BNP Paribas Financial Markets
ONCY

BNP Paribas Financial Markets’s Oncolytics Biotech ONCY Stock Holding History

BNP Paribas Financial Markets’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,884
Closed -$4.04K – 5895
2025
Q3 		$4.04K Buy
+2,884
New +$3.23K ﹤0.01% 5114
2025
Q1 		– Sell
-7,800
Closed -$7.13K – 5536
2024
Q4 		$7.13K Sell
7,800
-5,911
-43% -$6.15K ﹤0.01% 4891
2024
Q3 		$11.9K Buy
13,711
+11,811
+622% +$11.6K ﹤0.01% 3791
2024
Q2 		$1.88K Buy
+1,900
New +$2.07K ﹤0.01% 3817
2023
Q4 		– Sell
-22,400
Closed -$48.8K – 4067
2023
Q3 		$48.8K Sell
22,400
-45,920
-67% -$112K ﹤0.01% 3472
2023
Q2 		$178K Buy
68,320
+60,544
+779% +$101K ﹤0.01% 3056
2023
Q1 		$9.33K Buy
7,776
+7,176
+1,196% +$11.3K ﹤0.01% 3557
2022
Q4 		$978 Buy
+600
New +$911 ﹤0.01% 3808

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BNP Paribas Financial Markets's ONCY Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Oncolytics Biotech (ONCY) in Q4 2025, closing a stake of 2,884 shares — an estimated $4.04K sold.

BNP Paribas Financial Markets first reported a position in ONCY in Q4 2022 and held it in 8 quarters. The position peaked at $178K in Q2 2023. 61 funds tracked by Wall St. Rank hold ONCY as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Oncolytics Biotech position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,884 Oncolytics Biotech shares in Q4 2025, an estimated $4.04K.
  • BNP Paribas Financial Markets first reported a position in Oncolytics Biotech in Q4 2022 and held it in 8 quarters.
  • BNP Paribas Financial Markets's Oncolytics Biotech position peaked at $178K in Q2 2023.
  • 61 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.